Results 191 to 200 of about 23,087 (229)
Multifactorial hypophosphatemia: a diagnostic challenge involving denosumab, iron infusion, renal tubular acidosis, and gastrointestinal losses. [PDF]
JBMR PlusClifford L, Joshi T.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Osteoporosis Reports, 2022
To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation.Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss.
Anne Sophie Sølling +3 more
openaire +2 more sources
To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation.Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss.
Anne Sophie Sølling +3 more
openaire +2 more sources
Drugs of Today, 2011
Denosumab is a fully human monoclonal antibody that inhibits the formation, function and survival of osteoclasts, preventing the interaction of tumor necrosis factor ligand superfamily member 11 (receptor activator of nuclear factor kappa-B ligand, RANKL) with the tumor necrosis factor receptor superfamily member 11A (osteoclast differentiation factor ...
Cesar E, Bogado +4 more
openaire +2 more sources
Denosumab is a fully human monoclonal antibody that inhibits the formation, function and survival of osteoclasts, preventing the interaction of tumor necrosis factor ligand superfamily member 11 (receptor activator of nuclear factor kappa-B ligand, RANKL) with the tumor necrosis factor receptor superfamily member 11A (osteoclast differentiation factor ...
Cesar E, Bogado +4 more
openaire +2 more sources
Current Osteoporosis Reports, 2019
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple ...
Lamy O +3 more
openaire +3 more sources
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple ...
Lamy O +3 more
openaire +3 more sources
Expert Opinion on Drug Safety, 2013
Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand. It is an antiresorptive agent that reduces osteoclastogenesis.This drug evaluation reviews denosumab for use in osteoporosis. Denosumab has been shown to improve bone mineral density (BMD) and to reduce the incidence of new vertebral, hip and
Dima L, Diab, Nelson B, Watts
openaire +2 more sources
Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand. It is an antiresorptive agent that reduces osteoclastogenesis.This drug evaluation reviews denosumab for use in osteoporosis. Denosumab has been shown to improve bone mineral density (BMD) and to reduce the incidence of new vertebral, hip and
Dima L, Diab, Nelson B, Watts
openaire +2 more sources
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains [PDF]
Journal of Bone and Mineral Research, 2020 Discontinuation of denosumab is associated with a rapid return of bone mineral density (BMD) to baseline and an increased risk of multiple vertebral fractures.
Stephan Reichenbach +1 more
exaly +4 more sources
Denosumab for the treatment of osteoporosis
Osteoporosis and Sarcopenia, 2017 Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients
Michael McClung
exaly +2 more sources
Current Opinion in Rheumatology, 2009
Denosumab is an investigational fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand, an essential mediator of osteoclastic bone resorption. Receptor activator of nuclear factor kappaB ligand plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheumatoid arthritis, and bone loss ...
openaire +2 more sources
Denosumab is an investigational fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand, an essential mediator of osteoclastic bone resorption. Receptor activator of nuclear factor kappaB ligand plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheumatoid arthritis, and bone loss ...
openaire +2 more sources